TRIAL IN PROGRESS: PHASE I DOSE-ESCALATION STUDY OF VSV-GP (BI 1831169) MONOTHERAPY AND WITH EZABENLIMAB (BI 754091) IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

被引：0
|
作者：
Porosnicu, Mercedes [1 ]
Quinson, Anne-Marie [2 ]
MacKay, Abi [3 ]
Luecke, Stephan [4 ]
Lauer, Ulrich M. [5 ]
机构：
[1] Wake Forest Sch Med, Winston Salem, NC USA
[2] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA
[3] Boehringer Ingelheim Ltd, Bracknell, Berks, England
[4] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany
[5] Univ Tubingen Hosp, Tubingen, Germany
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷
关键词：
D O I：
10.1136/jitc-2022-SITC2022.0628
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
628
引用
收藏
页码：A660 / A660
页数：1
相关论文
共 50 条
  • [1] Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors
    Porosnicu, Mercedes
    Quinson, Anne-Marie
    Crossley, Kate
    Luecke, Stephan
    Lauer, Ulrich M.
    FUTURE ONCOLOGY, 2022, 18 (24) : 2627 - 2638
  • [2] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 (ezabenlimab) and BI 754111 in patients (pts) with advanced solid tumors.
    Yamamoto, Noboru
    Hafez, Navid
    Tolcher, Anthony W.
    Teufel, Michael
    Geng, Junxian
    Svensson, Liz
    Lahmar, Mehdi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Updated results from the phase I 1456-0001 study for intratumoral (IT) VSV-GP (BI 1831169) in patients with advanced solid tumors
    Champiat, S.
    Italiano, A.
    Wagle, N.
    Prenen, H.
    Greillier, L.
    Bourien, H.
    Whitman, E.
    Quinson, A-M.
    Luecke, S.
    Hern, V.
    Lauer, U.
    ANNALS OF ONCOLOGY, 2024, 35 : S693 - S693
  • [4] A phase Ia/Ib, dose-escalation/expansion study of BI 907828 in combination with BI 754091 and BI 754111 in patients (pts) with advanced solid tumors.
    Tolcher, Anthony W.
    Hafez, Navid
    Yamamoto, Noboru
    Park, Jaehong
    Grempler, Rolf
    Lucarelli, Anthony G.
    Lahmar, Mehdi
    Wang, Bushi
    Gounder, Mrinal M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] First results for intravenous (IV) VSV-GP (BI 1831169) in patients (pts) with advanced solid tumors from the 1456-0001 study
    Oliva Bernal, M.
    Greillier, L.
    Ponz-Sarvise, M.
    Moreno Garcia, V.
    Prenen, H.
    Wolf, D.
    Quinson, A-M.
    Luecke, S.
    Hern, V.
    Porosnicu, M.
    ANNALS OF ONCOLOGY, 2024, 35 : S693 - S694
  • [6] A phase I, open-label, dose-escalation trial of BI 1701963 as monotherapy and in combination with trametinib in patients with KRAS mutated advanced or metastatic solid tumors.
    Gort, Eelke
    Johnson, Melissa Lynne
    Hwang, Jimmy J.
    Pant, Shubham
    Dunzinger, Ulrich
    Riemann, Kathrin
    Kitzing, Thomas
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [7] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [8] Phase I dose-escalation trial of BI 1701963 with or without BI 3011441 in patients with KRAS-mutated solid tumors
    Chia, Lin C.
    CANCER SCIENCE, 2022, 113 : 953 - 953
  • [9] Phase Ia dose-escalation trial with the BET protein inhibitor BI 894999 in patients with advanced or metastatic solid tumours
    Schoffski, Patrick
    Machiels, Jean -Pascal
    Rottey, Sylvie
    Sadrolhefazi, Behbood
    Musa, Hanny
    Marzin, Kristell
    Awada, Ahmad
    EUROPEAN JOURNAL OF CANCER, 2023, 191
  • [10] A phase I dose escalation study of the LRP5 antagonist BI 905681 in patients with advanced and metastatic solid tumors
    Spigel, D. R.
    Wang, J. S.
    Pronk, L.
    Muskens, B.
    Teufel, M.
    Bashir, B.
    Burris, H.
    ESMO OPEN, 2024, 9 (11)
12345